Back

Lipid-lowering therapy use and LDL-C goal achievement in patients with hypercholesterolaemia or mixed dyslipidaemia in Hong Kong: findings from a retrospective database study

30 August 2026 (14:15 - 15:00)
Organised by: Logo
Congress Presentation Part of: Lipid lowering (3) Drug therapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Professor Bryan Ping Yen Yan

The Chinese University of Hong Kong, Hong Kong (China)

5 More presentations in this session

Presentation thumbnail
Improving LDL-C goal attainment: real-world outcomes and the impact of guideline optimization
Doctor R. Rached (DK)
Abstract Slides
Presentation thumbnail
Statin-free PCSK9 inhibitor therapy versus high-intensity atorvastatin for primary prevention: a target trial emulation study
Associate Professor C. Hsu (Taipei, TW)
Abstract Slides
Presentation thumbnail
Achievement of LDL‑C targets in clinical practice in Spain: a comparison between Observatory II and Observatory I
Doctor J. Cosin Sales (Valencia, ES)
Abstract Slides
Presentation thumbnail
Evolocumab for high cardiovascular risk patients without previous stroke: a network meta-analysis of randomized controlled trials
Mr S. Phutinart (Bangkok, TH)
Abstract Slides
Presentation thumbnail
Suboptimal LDL cholesterol target achievement in cardiac ATTR amyloidosis despite disease-modifying therapy
Doctor M. Pollak (Berlin, DE)
Abstract Slides

Access the full session

Session thumbnail
Lipid lowering (3)

The Event

Event poster

ESC Congress 2026

30 August 2026 14:15 CET
You may be interested in
thumbnail
Congress Presentation
LDL-C goal achievement and lipid-lowering therapy in patients by atherosclerotic cardiovascular disease subtype: the SANTORINI study
27 August 2022
thumbnail
Congress Presentation
Therapeutic gaps in low-density lipoprotein cholesterol management have narrowed over time but remain wide: a wide study of 40,141 acute coronary syndrome patients from 2016 to 2021
26 August 2023
thumbnail
Congress Presentation
VICTORION-Mono China: efficacy and safety of inclisiran as monotherapy in Chinese adults with low or moderate ASCVD risk and elevated LDL-C
29 August 2025
thumbnail
Congress Presentation
Review on clinical strategies for managing patients with elevated Lp(a): Cost-effectiveness of Lp(a) testing and awareness of lifestyle changes via Public Health Policy in absence of targeted therapy
24 June 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources